Propofol and malignant hyperthermia susceptibility.
Pollock
A N
AN
McKenzie
A J
AJ
Hodges
M
M
Snoeck
M M
MM
D000138:Acidosis / Q000209:etiology; D000293:Adolescent; D000328:Adult; D000368:Aged; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000209:etiology; D002423:Cause of Death; D002648:Child; D002675:Child, Preschool; D003620:Dantrolene / Q000627:therapeutic use; D004198:Disease Susceptibility; D005334:Fever / Q000209:etiology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects*; D007223:Infant; D008305:Malignant Hyperthermia / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D015742:Propofol / Q000008:administration & dosage / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000209:etiology; D012307:Risk Factors
D018686:Anesthetics, Intravenous; D006993:Hypnotics and Sedatives; D009125:Muscle Relaxants, Central; D003620:Dantrolene; D015742:Propofol